By influencing the balance between M1 and M2 polarization, NEU1-mediated changes in EV glycosylation can contribute to the inflammatory environment characteristic of AD, highlighting the potential for NEU1 as a therapeutic target. Here, NEU1 is linked to Alzheimer disease.